Dr. Lal PathLabs (NSE:LALPATHLAB) Debt-to-Equity : 0.07 (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Dr. Lal PathLabs Debt-to-Equity?

Dr. Lal PathLabs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹548 Mil. Dr. Lal PathLabs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹1,026 Mil. Dr. Lal PathLabs's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ₹21,727 Mil. Dr. Lal PathLabs's debt to equity for the quarter that ended in Mar. 2025 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dr. Lal PathLabs's Debt-to-Equity or its related term are showing as below:

NSE:LALPATHLAB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.13 Max: 0.35
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Dr. Lal PathLabs was 0.35. The lowest was 0.07. And the median was 0.13.

NSE:LALPATHLAB's Debt-to-Equity is ranked better than
79.69% of 192 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs NSE:LALPATHLAB: 0.07

Dr. Lal PathLabs Debt-to-Equity Historical Data

The historical data trend for Dr. Lal PathLabs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr. Lal PathLabs Debt-to-Equity Chart

Dr. Lal PathLabs Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Debt-to-Equity

Get a 7-Day Free Trial

0.12

0.35

0.25

0.13

0.07

Dr. Lal PathLabs Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Equity	Get a 7-Day Free Trial															0.13	N/A	0.10	N/A	0.07

Competitive Comparison of Dr. Lal PathLabs's Debt-to-Equity

For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr. Lal PathLabs's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dr. Lal PathLabs's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Dr. Lal PathLabs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dr. Lal PathLabs's Debt to Equity Ratio for the fiscal year that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(548	+	1026)	/	21727
	=	0.07

Dr. Lal PathLabs's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(548	+	1026)	/	21727
	=	0.07

Dr. Lal PathLabs (NSE:LALPATHLAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dr. Lal PathLabs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dr. Lal PathLabs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr. Lal PathLabs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

539524:India

Address

12th Floor, Tower B, SAS Tower, Sector 38, Medicity, Gurugram, HR, IND, 122 001

Website

https://www.lalpathlabs.com

Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the area of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist to prevent, monitor and treat diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.

Dr. Lal PathLabs Headlines

No Headlines